罗沙司他治疗肾性贫血引起横纹肌溶解症 1 例报告。
A case report of rhabdomyolysis caused by the use of roxadustat in the treatment caused by renal anaemia.
机构信息
Department of Nephrology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China.
出版信息
Int J Clin Pract. 2021 Jun;75(6):e14011. doi: 10.1111/ijcp.14011. Epub 2021 Jan 25.
CASE PRESENTATION
In this case, we share a case of one of our patients developed rhabdomyolysis after he was administered roxadustat to treat anaemia caused by chronic renal failure.
DISCUSSION
More than 1.2 million people died from chronic kidney damage (CKD) globally, in 2017. Anaemia is a common complication of CKD. Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and regulates iron metabolism. Roxadustat is often used to treat anaemia caused by renal failure. Its adverse effects include high blood pressure, myocardial infarction, heart failure, high potassium, and dizziness; however, there are no reports about rhabdomyolysis associated with roxadustat.
CONCLUSION
Physicians should be alert about the occurrence of rhabdomyolysis when roxadustat is used.
病例介绍
本例中，我们分享了一位患者的病例，他在接受罗沙司他治疗因慢性肾衰竭引起的贫血后出现横纹肌溶解症。
讨论
2017 年，全球有超过 120 万人死于慢性肾脏损害（CKD）。贫血是 CKD 的常见并发症。罗沙司他是一种口服低氧诱导因子脯氨酰羟化酶抑制剂，可刺激红细胞生成和调节铁代谢。罗沙司他常用于治疗肾衰竭引起的贫血。其不良反应包括高血压、心肌梗死、心力衰竭、高钾血症和头晕；然而，目前尚无关于罗沙司他引起横纹肌溶解症的报告。
结论
当使用罗沙司他时，医生应警惕横纹肌溶解症的发生。
Zotero 插件